dcsimg Aranesp® (darbepoetin alfa) – Transfusion Trends
› Email› Print

According to CMS, the average monthly transfusion rate rose by 19%
between 2010 and 20111

  • CMS will continue to monitor the rate of transfusions.1
Transfusion Trends

Important Safety Information

  • In controlled clinical trials, ESAs increased the risk of death in patients undergoing coronary artery bypass graft surgery (CABG) and the risk of deep venous thrombosis (DVT) in patients undergoing orthopedic procedures.
  • Control hypertension prior to initiating and during treatment with Aranesp®.

Scroll down for additional
Important Safety Information.

Abbreviations and References:
CMS = Centers for Medicare & Medicaid Services; ESA = erythropoiesis-stimulating agent; ESRD = end-stage renal disease; USRDS = United States Renal Data System.
References: 1. Collins AJ. ESRD payment policy changes: the new “bundled” dialysis Prospective Payment System (PPS) in the United States. Available at: http://www.usrds.org/presentations2012.aspx. Accessed July 2012. United States Renal Data System. Bethesda, MD: National Institutes of Health, National Institute of Diabetes and Digestive and Kidney Diseases; 2011. 2. Centers for Medicare & Medicaid Services. Medicare program: end-stage renal disease prospective payment system, quality incentive program, and bad debt reductions for all Medicare providers. [CMS-1352-P]. Fed Regist. 2012;77:40952-41000. 42 CFR Parts 413 and 417.

Biotechnology by Amgen®